Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | SHBG | P04278 | 1/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.62 |
| ▸ | GABRP | O00591 | 2/20 | 0.61 |
| ▸ | GABRD | O14764 | 2/20 | 0.61 |
| ▸ | G6PD | P11413 | 2/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18891600 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL8074397 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL598580 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL598581 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL7413090 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL7418009 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL14027906 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL14149787 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL3644724 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL6241057 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2879657-B1 | NOVEL SIRT1 ACTIVATORS AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING THEM | CENTRE NAT RECH SCIENT (FR) | 2019-11-13 | — | — | EP | claimed |
| US-20230117905-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES | ASARINA PHARMA AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11534446-B2 | Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties | ASARINA PHARMA AB (SE) | 2022-12-27 | — | — | US | disclosed |
| EP-2879657-B1 | NOVEL SIRT1 ACTIVATORS AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING THEM | CENTRE NAT RECH SCIENT (FR) | 2019-11-13 | — | — | EP | disclosed |
| CN-110167532-A | The suspension of injectable | 阿沙里那制药公司 | 2019-08-23 | — | — | CN | disclosed |
| US-20170258809-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES | ASARINA PHARMA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9687496-B2 | Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties | ASARINA PHARMA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| EP-2523666-B1 | A PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES | UMECRINE MOOD AB (SE) | 2016-01-13 | — | — | EP | disclosed |
| US-20150164914-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES | RELMADA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20120322781-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES | UMECRINE MOOD AB (SE) | 2012-12-20 | — | — | US | disclosed |
| EP-2523666-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES | Umecrine Mood AB (SE) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011087441-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES | UMECRINE MOOD AB (SE) | 2011-07-21 | — | — | WO | disclosed |
| US-20080255076-A1 | Steroid-Derived Pharmaceutical Compositions | JADOLABS GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1789056-A1 | USE OF STEROID-DERIVED PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS RELATING TO PATHOLOGICAL PROCESSES IN LIPID RAFTS | Jado Technologies GmbH (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006002907-A1 | USE OF STEROID-DERIVED PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS RELATING TO PATHOLOGICAL PROCESSES IN LIPID RAFTS | JADOLABS GMBH (DE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1458399-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | Umecrine AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003059357-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255076-A1 | Steroid-Derived Pharmaceutical Compositions | CYP11A1, CYP11B2, CYP11B1 | LMNA 937/4885GPBAR1 56/4885CYP3A4 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.